The Triple-Agonist Breakthrough
Retatrutide (LY3437943) is Eli Lilly’s triple-receptor agonist — the first drug to simultaneously target GLP-1, GIP, and glucagon receptors. It represents the next evolution in incretin-based weight loss treatment, following semaglutide (single-agonist) and tirzepatide (dual-agonist).
The Phase 3 results from Lilly’s TRIUMPH program confirmed what Phase 2 suggested: retatrutide produces the most weight loss of any pharmacological treatment ever studied.
The TRIUMPH Phase 3 Program
Eli Lilly announced top-line results from the TRIUMPH Phase 3 clinical trial program in late 2025:
Key Results
| Metric | Result |
|---|---|
| Average weight loss | 71.2 lbs (approximately 25–27% of body weight) |
| Treatment duration | 48–72 weeks (varies by trial arm) |
| Dose | Up to 12 mg weekly |
| Route | Weekly subcutaneous injection |
| Titration period | 24 weeks to maximum dose |
Comparison to Existing Drugs
| Drug | Mechanism | Max Weight Loss | Timeline | FDA Status |
|---|---|---|---|---|
| Retatrutide | GLP-1 + GIP + Glucagon | ~25–27% (71.2 lbs avg) | 48–72 weeks | Phase 3 complete |
| Tirzepatide | GLP-1 + GIP | 22.5% | 72 weeks | Approved |
| Semaglutide | GLP-1 | 14.9% | 68 weeks | Approved |
Retatrutide achieves more weight loss in less time than either approved drug.
Why the Third Receptor Matters
The Glucagon Difference
Semaglutide reduces food intake (GLP-1). Tirzepatide reduces food intake AND improves fat metabolism (GLP-1 + GIP). Retatrutide does both AND increases energy expenditure (GLP-1 + GIP + glucagon).
What glucagon receptor agonism adds:
-
Increased energy expenditure — glucagon activates thermogenesis, meaning your body burns more calories at rest. This is the mechanism that separates retatrutide from everything else. Other GLP-1 drugs reduce intake without increasing expenditure; retatrutide does both.
-
Hepatic fat oxidation — glucagon promotes fat burning in the liver, directly targeting visceral and hepatic fat. Phase 2 data showed dramatic liver fat reduction in subjects with NAFLD/NASH.
-
Glycogen mobilization — glucagon releases stored glucose from the liver, supporting energy balance during reduced caloric intake.
The Weight Loss Equation
| Drug | Reduced Intake | Improved Fat Metabolism | Increased Expenditure |
|---|---|---|---|
| Semaglutide | Yes (GLP-1) | No | No |
| Tirzepatide | Yes (GLP-1) | Yes (GIP) | No |
| Retatrutide | Yes (GLP-1) | Yes (GIP) | Yes (Glucagon) |
This three-pronged approach explains why retatrutide produces more weight loss faster — it attacks the energy balance equation from every angle simultaneously.
The Phase 2 Data That Predicted This
The Phase 2 trial (Jastreboff AM et al., New England Journal of Medicine, 2023) provided the foundation:
Phase 2 Results by Dose
| Dose Group | Weight Loss at 48 Weeks | Notes |
|---|---|---|
| Retatrutide 1 mg | -8.7% | Subtherapeutic |
| Retatrutide 4 mg (starting) | -17.1% | Meaningful but submaximal |
| Retatrutide 4 mg (maintenance) | -22.8% | Approaching tirzepatide-level |
| Retatrutide 8 mg (starting) | -22.1% | Strong response |
| Retatrutide 8 mg (maintenance) | -24.2% | Maximum efficacy |
| Retatrutide 12 mg | -24.2% | No additional benefit over 8 mg maintenance |
| Placebo | -2.1% | Baseline |
Key finding: At the 8 mg maintenance dose, 100% of participants (all of them) lost at least 5% of body weight. 93% lost at least 10%. 83% lost at least 15%. 63% lost at least 20%. These response rates are unprecedented.
Liver Fat Reduction
In participants with NAFLD (non-alcoholic fatty liver disease):
- 86% achieved normal liver fat levels (<5% hepatic fat fraction) at 48 weeks
- This compares to ~50% normalization with tirzepatide and ~30% with semaglutide at similar timepoints
This positions retatrutide as potentially transformative for the NAFLD/NASH epidemic — a condition affecting ~30% of adults in developed countries with no FDA-approved treatment beyond lifestyle modification.
Safety Profile
What We Know
| Side Effect | Frequency | Comparison |
|---|---|---|
| Nausea | 25–35% | Similar to tirzepatide |
| Diarrhea | 20–25% | Similar to tirzepatide |
| Constipation | 15–20% | Similar to tirzepatide |
| Vomiting | 10–20% | Similar to tirzepatide |
| Decreased appetite | Expected | Mechanism of action |
| Heart rate increase | Mild-moderate | Potentially more than dual-agonists (glucagon effect) |
What We Don’t Know
- Cardiovascular outcomes — no MACE reduction data (unlike semaglutide’s SELECT trial). This is the biggest data gap.
- Long-term safety — Phase 3 data is 48–72 weeks. Multi-year safety is unknown.
- Thyroid cancer risk — rodent MTC signal is present (boxed warning expected, same as semaglutide and tirzepatide).
- Lean mass preservation — detailed body composition data from Phase 3 is pending. Phase 2 suggested significant fat mass reduction; lean mass data is limited.
- Discontinuation effects — weight regain rate after stopping retatrutide is unknown but expected to follow the same pattern as other GLP-1 drugs (weight returns over 6–12 months).
The Glucagon Safety Question
Glucagon is diabetogenic — it raises blood sugar. The concern: does retatrutide’s glucagon component worsen glucose control?
Phase 2 data suggests not at a clinically meaningful level. The GLP-1 and GIP components’ insulin-sensitizing effects appear to counterbalance glucagon’s glucose-raising effect. In fact, retatrutide improved glycemic control in diabetic participants more than either semaglutide or tirzepatide individually. However, close glucose monitoring is essential, particularly in diabetic patients.
Timeline to Availability
| Milestone | Expected Timing |
|---|---|
| Phase 3 top-line results | Completed (late 2025) |
| Full Phase 3 publications | 2026 |
| NDA submission to FDA | 2026 |
| FDA review and decision | 2027 (estimated) |
| Commercial launch | 2027–2028 (if approved) |
Current availability: Research-grade retatrutide is available from peptide vendors at approximately $150–300/month. Quality control is less established than for semaglutide or tirzepatide — demand third-party CoA with HPLC and mass spectrometry verification.
What This Means for You
If You’re Currently on Semaglutide or Tirzepatide
There is no reason to switch to research-grade retatrutide while approved drugs are working for you. Retatrutide’s advantage is magnitude of weight loss — if your current drug is producing adequate results, the FDA-approved option with more safety data is the better choice.
Consider retatrutide research-grade if:
- You’ve plateaued on maximum-dose tirzepatide
- You need more aggressive weight loss than tirzepatide provides
- You understand and accept the investigational status and limited safety data
If You’re Starting Fresh
If you’re beginning a GLP-1 weight loss protocol in 2026:
- Standard path: Start with semaglutide or tirzepatide — FDA-approved, well-characterized, proven safety
- If those aren’t sufficient: Consider retatrutide after trying FDA-approved options
- Wait for approval: If you can wait 1–2 years, pharmaceutical-grade retatrutide with full prescribing information will likely be available by 2027–2028
The Research Community Perspective
For those using research-grade peptides and comfortable with the investigational status, retatrutide is the most potent weight loss peptide available. Full dosing protocol: Retatrutide Protocol.
Related Resources
- Retatrutide Protocol — full dosing, titration, and safety guide
- Semaglutide vs Tirzepatide — head-to-head comparison of approved drugs
- Weight Loss Peptides Compared — all weight loss options
- Semaglutide Protocol — FDA-approved GLP-1 protocol
- Tirzepatide Protocol — FDA-approved dual-agonist protocol
- Peptide Legality Guide — legal status of research peptides
Frequently Asked Questions
How much weight does retatrutide cause you to lose? +
In Phase 2 trials, retatrutide 12 mg produced an average 24.2% body weight loss (approximately 58 lbs for a 240 lb person) at 48 weeks. Phase 3 data from the TRIUMPH program showed an average of 71.2 lbs lost. This is the highest weight loss ever recorded for a pharmacological treatment — exceeding both semaglutide (14.9%) and tirzepatide (22.5%) at their respective trial endpoints.
When will retatrutide be FDA-approved? +
Eli Lilly's TRIUMPH Phase 3 program reported top-line results in late 2025. Based on typical FDA review timelines, a New Drug Application (NDA) submission is expected in 2026 with potential approval in 2027. However, FDA timelines can shift. Retatrutide is not yet available by prescription — it is only available as a research chemical.
How does retatrutide compare to tirzepatide? +
Retatrutide adds a third receptor target (glucagon) on top of tirzepatide's two (GLP-1 + GIP). Glucagon increases energy expenditure and promotes hepatic fat oxidation. In clinical data, retatrutide achieved 24.2% weight loss at 48 weeks vs tirzepatide's 22.5% at 72 weeks — faster and more total weight loss. However, tirzepatide is FDA-approved and has more safety data.
What are retatrutide's side effects? +
GI side effects are the most common — nausea (25–35%), diarrhea (20–25%), constipation (15–20%), and vomiting (10–20%). These are comparable to tirzepatide and generally manageable with proper dose titration. The glucagon component may theoretically increase heart rate more than dual-agonists. Comprehensive safety data from Phase 3 trials is pending full publication.
Can I get retatrutide now? +
Retatrutide is not FDA-approved and is not available by prescription. Research-grade retatrutide is available from peptide vendors as a research chemical labeled 'not for human consumption.' Quality control and source reliability are less established than for semaglutide or tirzepatide. Cost is approximately $150–300/month for research-grade. See our Retatrutide Protocol page for dosing and safety information.